republic-os/legislation/us/states/md/2020/hb-652.md

type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags

type	title	description	jurisdiction	legislature	session	identifier	citation	classification	subjects	status	primary_sponsors	version_count	action_count	vote_count	first_action	last_action	source	source_identifier	source_url	source_hash	vintage	source_snapshot	retrieved_at	confidence	tags
Bill	Maryland Medical Assistance Program and Health Insurance – Specialty Drugs – Definition	Maryland Medical Assistance Program and Health Insurance – Specialty Drugs – Definition	us/states/md	Maryland General Assembly	2020	HB 652	Maryland HB 652 (2020)	bill		enacted	Adams Anderton Arikan Bagnall Belcastro Bhandari Carr Charles Chisholm Clark Cullison Hill Hornberger Johnson K. Young Kelly Kerr Kipke Krebs Malone McComas Metzgar Morgan Pena-Melnyk Pendergrass R. Lewis Reilly Rosenberg Saab Szeliga	3	12	1	2020-01-29	2020-05-08	openstates	ocd-bill/52967f0a-a521-4ec8-a4ce-ba608eb58eeb	http://mgaleg.maryland.gov/mgawebsite/Legislation/Details/hb0652?ys=2020RS&search=True	f764666c36820739a21859bcaa8a65e93f6c968fd5acba67418b9c0e16ed13a4	2026-07-01	https://data.openstates.org/daily/2026-07-01/public.pgdump	2026-07-06	reported	legislation bill us-md

Maryland HB 652 (2020) — Maryland Medical Assistance Program and Health Insurance – Specialty Drugs – Definition

Version chain

The bill's text revisions, in order — the diff chain from filing to enrollment.

1. Chapter - Maryland Medical Assistance Program and Health Insurance – Specialty Drugs – Definition (committee substitute) — source
2. First - Maryland Medical Assistance Program and Health Insurance – Specialty Drugs – Definition (committee substitute) — source
3. Third - Maryland Medical Assistance Program and Health Insurance – Specialty Drugs – Definition (committee substitute) — source

Votes

• On Third Reading (Emerg) — 133–0 (pass) · lower

Sponsors

• Adams — primary (person)
• Anderton — primary (person)
• Arikan — primary (person)
• Bagnall — primary (person)
• Belcastro — primary (person)
• Bhandari — primary (person)
• Carr — primary (person)
• Charles — primary (person)
• Chisholm — primary (person)
• Clark — primary (person)
• Cullison — primary (person)
• Hill — primary (person)
• Hornberger — primary (person)
• Johnson — primary (person)
• K. Young — primary (person)
• Kelly — primary (person)
• Kerr — primary (person)
• Kipke — primary (person)
• Krebs — primary (person)
• Malone — primary (person)
• McComas — primary (person)
• Metzgar — primary (person)
• Morgan — primary (person)
• Pena-Melnyk — primary (person)
• Pendergrass — primary (person)
• R. Lewis — primary (person)
• Reilly — primary (person)
• Rosenberg — primary (person)
• Saab — primary (person)
• Szeliga — primary (person)

Timeline

The legislative action history — every referral, reading, and vote.

• 2020-01-29 First Reading Health and Government Operations referral-committee
• 2020-02-06 Hearing 2/27 at 1:00 p.m.
• 2020-03-12 Favorable with Amendments Report by Health and Government Operations committee-passage-favorable
• 2020-03-12 Favorable with Amendments { committee-passage-favorable
• 2020-03-12 Second Reading Passed with Amendments
• 2020-03-12 Third Reading Passed passage
• 2020-03-13 Referred Finance referral-committee
• 2020-03-15 Favorable Report by Finance committee-passage-favorable
• 2020-03-15 Favorable Adopted Second Reading Passed committee-passage-favorable
• 2020-03-16 Third Reading Passed passage
• 2020-03-17 Returned Passed
• 2020-05-08 Enacted under Article II, Section 17(c) of the Maryland Constitution - Chapter 614 became-law

Source

OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/52967f0a-a521-4ec8-a4ce-ba608eb58eeb. Confidence: reported (aggregated from official Maryland legislature records).